Form 4: Biodesix Chairman John Patience Boosts Equity Holdings

Biodesix Chairman John Patience reported new grants of restricted stock units and stock options, alongside the conversion of previously vested RSUs into common stock.

Summary

• John Patience, Chairman and Director of Biodesix Inc. (BDSX), reported changes in his beneficial ownership.
• On January 2, 2026, he was granted 5,443 Restricted Stock Units (RSUs) and 6,354 stock options with an exercise price of $6.46.
• These newly granted RSUs and stock options are scheduled to vest in four substantially equal installments on March 31, June 30, September 30, and December 31, 2026.
• On January 5, 2026, 1,143 previously vested RSUs were converted into common stock.
• Following these transactions, Patience directly owns 22,661 shares of common stock.
• He also indirectly owns 107,664 shares via Patience Enterprises LP, 241,480 shares via John Patience Living Trust dated July 23, 1993, and 2,649 shares via his spouse.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates a positive sentiment as the Chairman is increasing his equity stake through grants and conversions, aligning his interests with shareholders. The transactions are routine equity compensation and not open market purchases, but still reflect continued commitment to the company.

Positives

• The acquisition of 5,443 Restricted Stock Units (RSUs) and 6,354 stock options indicates continued equity incentive and alignment of the Chairman's interests with shareholder value.
• The conversion of 1,143 previously vested RSUs into common stock increases direct ownership in the company.
• Transactions made under a Rule 10b5-1(c) plan suggest pre-planned, non-discretionary activity, which can be viewed as a structured approach to insider trading.

Future Outlook

NA

Industry Context

This filing reflects routine equity compensation for a director and chairman in the biotechnology or diagnostics industry, common for aligning executive interests with long-term company performance. The use of RSUs and stock options is a standard practice in the sector to incentivize leadership and retain key personnel.

Related Party Transactions

• Indirect beneficial ownership of 107,664 shares through Patience Enterprises LP, where the Reporting Person is the sole general partner.
• Indirect beneficial ownership of 241,480 shares through John Patience Living Trust dated July 23, 1993, where the Reporting Person is the sole trustee.
• Indirect beneficial ownership of 2,649 shares through spouse.

Stakeholder Impact

• Shareholders: Increased alignment of the Chairman's interests with shareholders through equity grants and conversions, potentially fostering long-term value creation.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned in this filing.

Next Steps

• Vesting of 5,443 Restricted Stock Units in four equal installments on March 31, June 30, September 30, and December 31, 2026.
• Vesting of 6,354 Stock Options in four equal installments on March 31, June 30, September 30, and December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants and conversions for the Chairman of Biodesix, John Patience, under a pre-arranged 10b5-1 plan. While the increase in equity holdings through RSUs and stock options aligns management's interests with shareholders, these are not open market purchases indicating a strong conviction buy. The transactions are expected and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or financial updates.

Keywords

Biodesix, BDSX, John Patience, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Corporate Governance, Beneficial Ownership, Rule 10b5-1